Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that dutasteride 0.5 mg/day improved hair growth in patients with androgenetic alopecia over six months but was associated with a higher prevalence of sexual dysfunction.

This study found that 0.5 mg of dutasteride significantly improved hair growth compared to placebo and was well tolerated over six months in men with male pattern hair loss.

This study suggests that dutasteride may be a viable alternative for Korean men with androgenetic alopecia who do not respond to finasteride, as it improved hair density and thickness in most participants.

This study reported that among postmenopausal women with female pattern hair loss, treatment with topical finasteride 0.5% and minoxidil 2% was more effective at improving hair condition than treatment with topical 17α-estradiol 0.05% and minoxidil 2%, particularly notable at 12-18 months of follow-up.

In this study, among 30 patients with androgenetic alopecia, topical Minoxidil was effective alone or in combination with either oral or microneedling-applied Dutasteride, with the microneedling approach offering promising results and fewer side effects compared to oral Dutasteride.

In this study, dutasteride 0.5 mg was found to provide long-term efficacy and safety in treating androgenetic alopecia in Korean men, with 89.9% showing improvement and 93.9% experiencing prevention of disease progression over at least 5 years.

This study observed that both intradermotherapy with 5% minoxidil and topical minoxidil application resulted in perceived improvements in hair density and thickness among patients with androgenetic alopecia, with no significant difference between the two groups.

This systematic review found that hair loss was more frequently observed in acne patients on isotretinoin doses ≥0.5 mg/kg/d compared to those on lower doses, suggesting dose-dependent effects.

This study found that five 0.1 mg dutasteride capsules are bioequivalent to one 0.5 mg dutasteride capsule in healthy adult males under fasting conditions, and both were well tolerated.

This study found that ethanolic and petroleum ether extracts of Cuscuta reflexa, as well as an isolate from these extracts, improved hair growth and follicle characteristics in androgen-induced alopecia in rats.

This study found that dutasteride 0.5 mg was generally well-tolerated and led to overall improvement in male patients aged 18 to 41 with androgenic alopecia in a Korean clinical practice setting.

This meta-analysis reported that 0.5 mg/d of dutasteride significantly increased total hair count at 24 weeks compared to finasteride and minoxidil in men with androgenetic alopecia.

This study found that among various treatments for male androgenetic alopecia, dutasteride 0.5 mg/day was the most effective option overall. Additionally, among FDA-approved treatments, topical minoxidil 5% was the most effective topical therapy, and finasteride 1 mg/day was the most effective oral therapy.

This study reported no significant difference in efficacy or sexual dysfunction risk between 5α-reductase inhibitors and placebo for androgenetic alopecia, suggesting that dutasteride 0.5 mg may be considered pending further research.

In this study, 0.2 mg dutasteride significantly improved hair growth in men with androgenetic alopecia compared to placebo over 24 weeks, showing similar efficacy to the higher 0.5 mg dose with a favorable safety profile.

The study concluded that dutasteride 0.5 mg daily for 24 weeks was the most effective monotherapy for increasing hair density in men with androgenetic alopecia, compared to other interventions.

In this study, finasteride doses as low as 0.2 mg per day significantly reduced both scalp skin and serum DHT levels in men with androgenetic alopecia.

This study found that finasteride significantly reduced prostate weight and DHT levels in male mastomys, but not in females, suggesting unique androgen metabolism in female prostates.

The researchers reported that oral finasteride 1 mg was associated with more frequent reports of sexual adverse events than dutasteride 0.5 mg, particularly after 2012, which may be influenced by the nocebo effect.

This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.

This study found that components derived from Uromedic® pumpkin seeds, especially Δ7-sterols, may inhibit DHT production and AR binding, potentially benefiting prostate and bladder health by moderating these mechanisms.

This study reports the development of a microemulsion using Momordica charantia extract, which demonstrated strong antioxidant and 5α-reductase inhibitory activity, potentially aiding hair loss management. The microemulsion was stable over 12 weeks, suggesting its future potential for cosmetic or pharmacological applications.

This study found that Cynanchi Wilfordii Radix has strong antioxidant activity and may reduce key factors involved in male hair loss in dermal papilla cells.

This study observed that dutasteride treatment led to improvement in acne vulgaris among two male patients with androgenetic alopecia, suggesting its potential as a treatment option for concurrent conditions.

This study developed a pharmacokinetic/pharmacodynamic model for finasteride, concluding that finasteride's nonlinear pharmacokinetics are likely due to its saturable binding to 5alphaR2.

This study found that certain curcumin analogs derived from natural plant sources exhibit anti-androgen activity by inhibiting steroid 5-alpha reductase, identifying key structural features for their potency and safety in treating androgen-related conditions.

This review provides an in-depth examination of the efficacy and safety of finasteride and dutasteride, commonly used for treating benign prostatic hyperplasia and male androgenetic alopecia.

In this randomized clinical trial, minoxidil at 5 mg was not found to be superior to 2.5 mg for treating male androgenetic alopecia over 24 weeks, though the higher dose more frequently caused side effects like pre-tibial edema and dizziness.

This review analyzes existing literature on prognostic factors for renal cell carcinoma, highlighting the need for continuous updates of prognostic models to reflect advancement in molecular pathway knowledge and targeted therapies.